Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study.

Clinical lung cancer - 1 Nov 2017

Jiang Tao, Cheng Ruirui, Zhang Guowei, Su Chunxia, Zhao Chao, Li Xuefei, Zhang Jie, Wu Fegnying, Chen Xiaoxia, Gao Guanghui, Li Wei, Cai Weijing, Zhou Fei, Zhao Jing, Xiong Anwen, Ren Shengxiang, Zhang Guojun, Zhou Caicun, Zhang Jun

Abstract excerpt

BACKGROUND: The risk factors for liver metastasis (LM) in patients with non-small-cell lung cancer (NSCLC) remain unknown. Whether LM predicts for the effect of first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant NSCLC needs to be explored. PATIENTS AND METHODS: A total of 598 NSCLC patients from 3 centers underwent EGFR testing, and 293 had...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Liver Neoplasms

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Smoking

Share to Survival Rate

Source

Identifiers

PMID: 28549835
DOI: 10.1016/j.cllc.2017.04.015

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study.PMID 28549835Read ↗

Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.Semantic proximity Read ↗

The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.Semantic proximity Read ↗

Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score-matched analysis.Semantic proximity Read ↗

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.Semantic proximity Read ↗

Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma.Semantic proximity Read ↗

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients.Semantic proximity Read ↗

Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.Semantic proximity Read ↗

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasisSemantic proximity Read ↗

Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases.Semantic proximity Read ↗

Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.